Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Drugs for Immunotherapy Market Expected to Grow Between 2025 And 2029?

The immunotherapy drugs market has witnessed a rapid expansion in recent years. It is projected to escalate from a market size of $255.14 billion in 2024 to $281.43 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. The substantial progress in the historical period is linked to the increasing prevalence of cancer, unfulfilled medical requirements, awareness related to cancer immunotherapy, the growing acceptance of immunotherapeutic methods, and the accelerating investments made by major pharmaceuticals.

What Growth Rate Is Anticipated for the Drugs for Immunotherapy Market in the Coming Years?

The immunotherapy drugs market is predicted to witness swift expansion in the coming years, reaching a valuation of $445.12 billion by 2029 at a compound annual growth rate (CAGR) of 12.1%. This projected growth can be credited to factors such as combination therapies, bespoke medicine, global spread, therapies driven by biomarkers, and an uptick in clinical trials. The period of forecast will be marked by significant trends such as progress in the field of immunology, enhancement in car-t cell therapies, targeted immunotherapy approaches, combinations of immunotherapies, and the development of neoantigen vaccines.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2559&type=smp

Who Are the Leading Companies in the Drugs for Immunotherapy Market?

Major companies operating in the drugs for immunotherapy market include F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson, UbiVac, Pfizer Inc., Sanofi SA, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Gilead Sciences Inc., Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

What Are the Key Drivers of the Drugs for Immunotherapy Market?

The immunotherapy drugs market is being propelled by a spike in cancer incidences worldwide. Obesity, smoking, alcohol consumption, and poor dietary habits are the primary contributors to most cancer types. For example, predictions from Macmillan Cancer Support, the UK’s largest healthcare charity organization, in October 2022 indicate that the cancer patient count will reach 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Breast, lung, colon, rectum, and prostate cancers are the most common forms of the disease. Factors such as tobacco usage, high body mass index, alcohol consumption, a diet low in fruits and vegetables, and lack of exercise contribute to about one-third of cancer-related deaths. As cancer incidences rise, it is anticipated that the demand for immunotherapy drugs will also surge, fuelling the growth of the immunotherapy drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2559&type=smp

What Are the Key Market Segments in the Drugs for Immunotherapy Industry?

The drugs for immunotherapy market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types

2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas

3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Interferons: Interferon Alfa, Interferon Beta, Interferon Gamma

3) By Interleukins: Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12)

4) By Vaccines: Preventive Vaccines, Therapeutic Vaccines

5) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

6) By Other Types: Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy

What Are the Latest Trends in the Drugs for Immunotherapy Market?

Leading firms in the immunotherapy drugs market have been streamlining efforts towards the innovation of new products, such as Keytruda (pembrolizumab), to deliver trustworthy services to their clients. Keytruda (pembrolizumab) represents a form of immunotherapy treatment which involves a targeted therapy drug classified as an immune checkpoint inhibitor and is designated for adult usage. For example, in January 2023, the U.S. based pharmaceutical conglomerate, Merck & Co., Inc., rolled out Keytruda (pembrolizumab). The release followed the green light from the Food and Drug Administration, a United States’ federal institution. The application of Keytruda (pembrolizumab) immunotherapy caters to treating a variety of cancer types, by synergizing with the human immune system to counteract cancer cells. Keytruda (pembrolizumab) has received the authorization for use as an adjunctive therapy for non-small cell lung cancer (NSCLC). This progression marks a major breakthrough in the realm of cancer therapy and is projected to influence the healthcare sector positively.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

What Are the Key Regional Markets in the Drugs for Immunotherapy Industry?

The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2559

This Report Delivers Insight On:

1. How big is the drugs for immunotherapy market, and how is it changing globally?

2. Who are the major companies in the drugs for immunotherapy market, and how are they performing?

3. What are the key opportunities and risks in the drugs for immunotherapy market right now?

4. Which products or customer segments are growing the most in the drugs for immunotherapy market?

5. What factors are helping or slowing down the growth of the drugs for immunotherapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model